The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Development and Assessment of LRRK2 Type II Inhibitors as Potential Therapeutics for Parkinson’s Disease
Study Rationale: LRRK2 is one of the best validated drug targets for Parkinson’s disease (PD). The LRRK2 inhibitors currently in development — called Type I inhibitors —bind to the closed, or active...
-
Research Grant, 2023Understand Me for Life: Using Noise-augmented Automatic Speech Recognition to Improve Intelligibility in Parkinson’s Disease
Study Rationale: Most people with Parkinson’s disease (PD) develop voice and speech problems at some point during the course of the disease. Such problems, collectively known as the motor speech...
-
Research Grant, 2023Evaluation of a Digital Therapeutics (DTx) Mobile App and Algorithm for Personalized Medication and Treatment Plan Optimization for People with Parkinson’s Disease
Study Rationale: People with Parkinson’s disease (PD) have few options for keeping their symptoms under control. An app that could automatically monitor PD symptoms, like tremors, could allow users to...
-
Translational Pipeline Program, 2022Prevention of Dementia in GBA-associated Parkinson’s Disease
Study Rationale: Whereas motor symptoms can be well controlled by dopamine-enhancing drugs and deep brain stimulation, dementia represents a key milestone in the course of Parkinson’s disease (PD)...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Targeting the Dopamine D1 Receptor for a Treatment of Parkinson’s Disease with Minimal L-DOPA-induced Dyskinesia
Study Rationale: L-DOPA is the primary drug used for treating the mobility loss that occurs in Parkinson’s disease (PD) due to decreases in dopamine. Although L-DOPA enhances mobility, chronic...
-
Translational Pipeline Program, 2023Evaluation of Glunomab, a Novel Immunotherapy for the Treatment of Parkinson’s Disease
Study Rationale: Glunomab is a monoclonal antibody that inhibits a toxic interaction between two proteins recently determined to be involved in the pathology of Parkinson’s disease (PD). Because its...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.